search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Industry News


ACG launches ACG Laboratories with a Process Development Lab in Shirwal, India


P


harma/nutra manufacturing solutions company ACG has added another specialist division to its


integrated global offering with the official inauguration of its first ACG Laboratories site, a process development laboratory in Shirwal, India dedicated to the collaborative exploration of all aspects of oral solid dosage manufacturing. As an extension of ACG’s broader customer service offering, the new lab allows ACG’s customers to explore and solve their manufacturing needs and challenges in a dedicated and state-of-the-art facility that also meets growing customer needs for training and assistance with clinical trials and development projects. The lab houses a dedicated R&D space for small-scale development, and a pilot area for scale-up and process optimization studies and is equipped to accommodate multiple projects at a time. The Shirwal Process Development Lab team comprises specialists in a number of areas including fluid bed and high shear mixer granulation, bottom spray pellet coating and drying, tablet compression and coating, as well capsule filling. On the launch of ACG


Laboratories, Dr Marcus Michel, CEO of ACG Engineering, said:


www.chemicalsknowledgehub.com


Pictured at the opening of ACG’s Process Development Lab in Shirwal, India are (left to right): Rajesh Menon, COO Operations, ACG Engineering; Shankar Gupta, President and CO, Sales, ACG Engineering; Marcus Michel, CEO, ACG Engineering; Geena Malhotra, President and Global Chief Technology Officer of Indian pharmaceutical company Cipla; Shirish Dhande, former President and CEO, ACG Pharma Technologies Pvt Ltd; Sandeep Raktate, Senior Vice President and Formulation Cluster Head, Cipla; and Shaju Thommana, General Manager Operations, ACG Engineering.


“We believe in constantly trying to make the life of our customers and end users easier and better. The lab’s multi-purpose functionality allows us to support our customers in a way of an aligned partnership throughout the product


development process. It provides a ‘go-to’’ knowledge hub for continuous support of the customer in various stages of product manufacturing across different oral solid dose applications. It is also a benchmark for our industry.


Indena is the first company in Italy authorized to produce CBD


Italian company Indena has been authorized by the Italian Ministry of Health and Italian Medicines Agency (AIFA) to produce cannabinoid-based cannabis extracts: the company will produce pharmaceutical-grade cannabidiol (CBD) for the global market for clinical and commercial use, making it one of the few companies in the


8


world able to produce cannabidiol (CBD) for the pharmaceutical market. CBD is an active ingredient obtained by extraction and isolation from the inflorescences and aerial parts of hemp (Cannabis sativa). The raw material for Indena’s CBD supply will be grown and processed in Italy. The company uses registered varieties of hemp


with a THC level of less than 0.2% in accordance with European standards and also guarantees a residual THC content of less than 0.02%, well below the limits defined by the FDA and the DEA, enabling Indena to submit the DMF (Drug Master File) for this product to the FDA. Cannabidiol (CBD) is an active


The recent situation has shown us how critical close collaboration and agility have become to reaching the end-user’s requirements. If ACG can be part of that evolution with our clients, then we’ll truly be living up to our ‘Make it better’ mission.”


pharmaceutical ingredient approved for seizures associated with some rare forms of childhood epilepsy (Lennox-Gastaud syndrome, Dravet syndrome and tuberous sclerosis complex) and is in clinical development for other forms of epilepsy. Furthermore CBD is under clinical investigation for schizophrenia, and for its therapeutic potential in other psychiatric disorders, neurological or autoimmune/inflammatory based diseases.


March/April 2021 • Issue 2


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64